RAPT Therapeutics, Inc. (RAPT) Dividend History

Company News

• RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

  RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced the appointment of Lori Lyons-Williams as the new chair of its board of directors, succeeding William Rieflin. Lyons-Williams is an industry veteran with over 20 years of experience in the pharmaceutical and biotech sectors.

  GlobeNewswire Inc.

  Featured Companies: CTNM
• Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data - Zacks Investment Research

  Agenus Inc. (AGEN) shares plunged 58.8% after the FDA discouraged the accelerated approval pathway for the company's immunotherapy combination botensilimab (BOT) and balstilimab (BAL) in relapsed/refractory microsatellite stable colorectal cancer. The FDA cited concerns that the observed objective response rate might not translate to a survival benefit.

  Zacks Investment Research

  Featured Companies: ADPT AGEN ANIP
• Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why - Zacks Investment Research

  Arcutis Biotherapeutics' Zoryve cream 0.15% has been approved by the FDA for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients aged six years and older. The approval is based on positive data from two phase III studies, and the company plans to make the drug widely available by the end of July.

  Zacks Investment Research

  Featured Companies: ADPT ANIP ARQT
• Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why - Zacks Investment Research

  Lisata Therapeutics' lead pipeline candidate, certepetide, has shown promising results in a preclinical study for treating intrahepatic cholangiocarcinoma, an aggressive form of cancer. The positive data underlines the potential of certepetide in improving the tumor environment and making tumors more responsive to immunotherapy.

  Zacks Investment Research

  Featured Companies: ADPT ANIP LSTA
• Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up - Zacks Investment Research

  Athira Pharma has dosed the last patient in the phase II/III LIFT-AD study evaluating its pipeline candidate, fosgonimeton, for the treatment of mild-to-moderate Alzheimer's disease. The study is designed to assess the treatment effects of fosgonimeton across multiple aspects of the disease.

  Zacks Investment Research

  Featured Companies: ACRV ADPT ATHA